Literature DB >> 25239421

Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

Rachel M Hagen1, Patricia Adamo1, Saima Karamat2, Jon Oxley2, Jonathan J Aning3, David Gillatt3, Raj Persad3, Michael R Ladomery1, Anthony Rhodes4.   

Abstract

OBJECTIVES: The proto-oncogene ETS-related gene (ERG) is consistently overexpressed in prostate cancer. Alternatively spliced isoforms of ERG have variable biological activities; inclusion of exon 11 (72 base pairs [bp]) is associated with aggressiveness and progression of disease. Exon 10 (81 bp) has also been shown to be alternatively spliced. Within this study, we assess whether ERG protein, messenger RNA (mRNA), and ERG splice isoform mRNA expression is altered as prostate cancer progresses.
METHODS: Detection of the TMPRSS2-ERG fusion was done using direct methods (reverse transcription polymerase chain reaction [PCR] and fluorescence in situ hybridization) and indirect methods for ERG mRNA and protein expression using quantitative PCR and immunohistochemistry, respectively. A linear equation method was used to quantitatively determine relative proportions of ERG variants (ERG72/Δ72, ERG81/Δ81) for each sample.
RESULTS: ERG mRNA and protein expression is increased in patients with advanced prostate cancer, with higher levels of ERG expression significantly associated with seminal vesicle invasion (stage pT3b) and biochemical recurrence. Genes involved in cell migration and invasiveness (matrix metalloproteinase 7, osteopontin, and septin 9) are increased in prostate cancers that overexpress ERG. In addition, there is a clear indication of increased retention of exons 10 and 11 in prostate cancer.
CONCLUSIONS: Analysis of ERG and its variants may be valuable in determining prognosis and development of prostate cancer. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  ERG isoforms; FFPE; Prostate cancer; TMPRSS2-ERG

Mesh:

Substances:

Year:  2014        PMID: 25239421     DOI: 10.1309/AJCPH88QHXARISUP

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

Review 1.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

2.  Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.

Authors:  Jouhyun Jeon; Ekaterina Olkhov-Mitsel; Honglei Xie; Cindy Q Yao; Fang Zhao; Sahar Jahangiri; Carmelle Cuizon; Seville Scarcello; Renu Jeyapala; John D Watson; Michael Fraser; Jessica Ray; Kristina Commisso; Andrew Loblaw; Neil E Fleshner; Robert G Bristow; Michelle Downes; Danny Vesprini; Stanley Liu; Bharati Bapat; Paul C Boutros
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

Review 3.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

4.  The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Authors:  Patricia Adamo; Sean Porazinski; Shavanthi Rajatileka; Samantha Jumbe; Rachel Hagen; Man-Kim Cheung; Ian Wilson; Michael R Ladomery
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

5.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Authors:  Martine P Roudier; Brian R Winters; Ilsa Coleman; Hung-Ming Lam; Xiaotun Zhang; Roger Coleman; Lisly Chéry; Lawrence D True; Celestia S Higano; Bruce Montgomery; Paul H Lange; Linda A Snyder; Shiv Srivastava; Eva Corey; Robert L Vessella; Peter S Nelson; Aykut Üren; Colm Morrissey
Journal:  Prostate       Date:  2016-03-16       Impact factor: 4.104

6.  Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.

Authors:  Vivekananda Kedage; Brady G Strittmatter; Paige B Dausinas; Peter C Hollenhorst
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

7.  A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.

Authors:  M J Donovan; M Noerholm; S Bentink; S Belzer; J Skog; V O'Neill; J S Cochran; G A Brown
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-09-08       Impact factor: 5.554

Review 8.  RNA splicing and splicing regulator changes in prostate cancer pathology.

Authors:  Jennifer Munkley; Karen Livermore; Prabhakar Rajan; David J Elliott
Journal:  Hum Genet       Date:  2017-04-05       Impact factor: 4.132

9.  Noninvasive Prenatal Diagnosis Significance of ERG Methylation as a Biomarker in Down's Syndrome.

Authors:  Xiangju Liu; Ming Xue
Journal:  Med Sci Monit       Date:  2017-01-23

Review 10.  Targeting Splicing in Prostate Cancer.

Authors:  Effrosyni Antonopoulou; Michael Ladomery
Journal:  Int J Mol Sci       Date:  2018-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.